MATE and DEA Compliance

Substance Use Disorders and Appropriate Pain Management to Meet New DEA Requirements

Choose from the CME activities listed below to satisfy the one-time 8-hour Drug Enforcement Administration (DEA) training requirement for DEA-registered physicians and advanced practitioners. The Medication Access and Training Expansion (MATE) Act requires new or renewing DEA licensees to have completed a total of at least 8 hours of training on opioid or other substance use disorders and the appropriate treatment of pain. The deadline to meet this requirement is the date of the practitioner’s next DEA registration.

CME Hero header

About MATE and DEA Compliance

Choose from the CME courses below to fulfill the 8-hour DEA requirement.

StatPearls has compiled a list of FAQs to address queries related to the MATE Act and the CME requirement, available here.


MATE Activities

Title Description Hours Questions

How to Fulfill the DEA-Training Requirement on StatPearls and FAQs

The MATE Act requires increased training for Drug Enforcement Administration (DEA)-registered physicians and practitioners—specifically, a one-time 8-hour training requirement on treating patients with opioid or other substance use disorders.

Key points to keep in mind on the new MATE Act training requirement and StatPearls resources

With more than 9,000 continuing education activities with PubMed-indexed original content and 68,000+ questions associated with those activities, StatPearls is the most comprehensive healthcare education resource in the world. Since 2014, more than 7,800 healthcare professional authors and editors have contributed to this noble effort.
As of June 27, 2023, practitioners are required to check a box on their online DEA registration form—regardless of whether a registrant is completing their initial registration application or renewing their registration—affirming that they have completed at least 8 hours of compliant and accredited training. The deadline is the date of the practitioner’s next DEA registration submission; it’s a one-time training requirement.
DEA licenses are renewed every 3 years.
Yes! StatPearls makes compliance easy. Please see StatPearls’ MATE course page on Opioid and Other Substance Use Disorders, Addiction Education, and Appropriate Treatment for Chronic Pain. Learners can customize their course package and work at their own pace to fulfill the 8-hour training requirement.
  • Physicians who are board-certified in addiction medicine or addiction psychiatry.

  • Practitioners who graduated from a medical, dental, physician assistant, or advanced practice nursing school within 5 years of June 27, 2023, and successfully completed a curriculum that included at least 8 hours of SUD training from an approved provider during that time.

  • Practitioners who previously took training to meet the requirements of the DATA-2000 waiver to prescribe buprenorphine can apply these hours toward the 8 hours required.

SAMHSA recommends that content should be related to the prevention, recognition, and care of people with substance use disorders including those with concurrent pain and/or psychiatric and medical comorbidities. Recommended core curricular training elements include substance use disorders, effective treatment planning, and pain management and substance misuse.
“Given the urgency of the nation’s overdose crisis, the importance of practitioners receiving training in substance use disorders (SUD) cannot be overstated. Incorporating training on SUD into routine healthcare will enable practitioners to screen more widely for substance use disorders, treat pain appropriately, prevent substance misuse, and engage people in life-saving interventions.”---SAMHSA
Yes. The ACCME will soon have functionality in PARS/JA-PARS to allow activities to be tagged for content and listed in an activity search that meets both the MATE Act requirements and those of relevant medical state licensing boards.
Yes. Learner activities reported into PARS and displayed in CME Passport are available for review directly by state licensing authorities and are recognized as primary source-verified reports by DEA and other national regulatory bodies.---ACCME

If you have questions for ACCME, please contact info@accme.org.

Questions for SAMHSA? Contact infobuprenorphine@samhsa.hhs.gov.

Questions for the DEA? ContactODLP@dea.gov.

Questions for StatPearls? Contact info@statpearls.com.